NEUCA S.A. (NEU) AI Stock Analysis

• Market Cap: zł3.14B
• Dividend Yield: 1.95%
• Average Volume (3M): 1.23K
• Price to Earnings (P/E): 23.7
• Beta (1Y): 0.51
• Revenue Growth: 7.55%
• EPS Growth: -19.28%
• Country: PL
• Employees: 4,633
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 6.01
• Shares Outstanding: 4,626,044
• 10 Day Avg. Volume: 1,049
• 30 Day Avg. Volume: 1,226
• PEG Ratio: -31.54
• Price to Book (P/B): 3.49
• Price to Sales (P/S): 0.27
• P/FCF Ratio: 9.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 47.73
• Revenue Forecast (FY): zł14.21B

• Rating: 59 Neutral
• Price Target: zł735.00 ▼(-12.91% Downside)
• Action: N/A Date: 09/14/25
• Date: Action: N/A 09/14/25

NEUCA S.A. receives an overall stock score of 59, primarily driven by mixed financial performance with stable balance sheet metrics but weak profitability and cash flow growth. Valuation appears reasonable with a moderate P/E ratio and dividend yield, while the lack of technical data limits momentum insights. The key risk lies in financial consistency, particularly cash flow volatility, which tempers optimism for near-term growth.

Positive Factors

Stable Margins

Stable margins indicate effective cost management and pricing strategies, supporting NEUCA's profitability and operational efficiency over time.

Negative Factors

Earnings Growth

Negative EPS growth reflects challenges in maintaining earnings momentum, which could impact NEUCA's ability to reinvest in its business and sustain shareholder returns.

NEUCA S.A. Business Overview & Revenue Model

Company Description

NEUCA S.A. engages in the distribution of pharmaceuticals to pharmacies and hospitals in Poland. It operates through Pharmaceutical Wholesale; Own Brands; and Outpatient Care Clinics, Clinical Trials and Telemedicine segments. The company also pro...

Read more

NEUCA S.A. engages in the distribution of pharmaceuticals to pharmacies and hospitals in Poland. It operates through Pharmaceutical Wholesale; Own Brands; and Outpatient Care Clinics, Clinical Trials and Telemedicine segments. The company also pro...

How the Company Makes Money

NEUCA generates revenue through several key streams. The primary source of income comes from the wholesale distribution of pharmaceuticals, which involves purchasing drugs from manufacturers and selling them to pharmacies and healthcare facilities...

Read more

NEUCA generates revenue through several key streams. The primary source of income comes from the wholesale distribution of pharmaceuticals, which involves purchasing drugs from manufacturers and selling them to pharmacies and healthcare facilities...

NEUCA S.A. Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	13.64B	12.61B	11.81B	11.23B	9.86B
Gross Profit	1.56B	1.44B	1.31B	1.24B	1.02B
EBITDA	360.38M	417.85M	401.82M	352.41M	293.42M
Net Income	155.58M	154.24M	146.27M	137.24M	150.66M
Balance Sheet
Total Assets	6.33B	5.51B	5.18B	4.84B	4.12B
Cash, Cash Equivalents and Short-Term Investments	168.62M	143.94M	119.55M	225.87M	89.18M
Total Debt	853.32M	448.57M	663.43M	378.08M	176.59M
Total Liabilities	5.06B	4.10B	4.12B	3.91B	3.23B
Stockholders Equity	1.06B	1.14B	990.36M	880.24M	847.29M
Cash Flow
Free Cash Flow	371.66M	-29.68M	194.09M	254.49M	247.45M
Operating Cash Flow	496.54M	63.23M	288.27M	335.94M	300.20M
Investing Cash Flow	-323.45M	-198.10M	-257.03M	-180.22M	-145.49M
Financing Cash Flow	-144.95M	139.62M	-139.09M	-6.64M	-112.76M

NEUCA S.A. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 844.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:NEU, the sentiment is Negative. The current price of 844 is above the 20-day moving average (MA) of 686.75, above the 50-day MA of 734.26, and above the 200-day MA of 739.44, indicating a bearish trend. The MACD of -21.43 indicates Negative momentum. The RSI at 43.25 is Neutral, neither overbought nor oversold. The STOCH value of 65.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PL:NEU.

NEUCA S.A. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NEU	59 Neutral	zł3.14B	23.74	14.63%	1.95%	7.55%	-19.28%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLN	51 Neutral	zł1.15B	77.86	―	0.43%	47.79%	―
SLV	51 Neutral	zł569.02M	975.15	-1.25%	―	14.10%	-99.00%
RVU	44 Neutral	zł554.88M	-6.19	-110.42%	―	15.45%	-25.81%